Aardvark Therapeutics Doses First Patient In Australia In HERO Phase 3 Trial For Prader-Willi Syndrome

Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout

Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to enroll

All patients who have completed HERO trial to date have successfully enrolled and remain in the Open Label Extension trial